Search

Your search keyword '"Borgström, F."' showing total 434 results
Start Over Author "Borgström, F."
434 results on '"Borgström, F."'

2. Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group

Author

Chotiyarnwong, P., McCloskey, E. V., Harvey, N. C., Lorentzon, M., Prieto-Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyere, O., Carey, J. J., Clark, P., Cooper, C., Curtis, E. M., Dennison, E., Diaz-Curiel, M., Dimai, H. P., Grigorie, D., Hiligsmann, M., Khashayar, P., Lewiecki, E. M., Lips, P., Lorenc, R. S., Ortolani, S., Papaioannou, A., Silverman, S., Sosa, M., Szulc, P., Ward, K. A., Yoshimura, N., and Kanis, J. A.

Published
2022
Full Text
View/download PDF

3. Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS)

Author

Talevski, J., Sanders, K.M., Watts, J.J., Nicholson, G.C., Seeman, E., Iuliano, S., Prince, R., March, L., Winzenberg, T., Duque, G., Ebeling, P.R., Borgström, F., Kanis, J.A., Stuart, A.L., Beauchamp, A., and Brennan-Olsen, S.L.

Published
2022
Full Text
View/download PDF

11. Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK

Author

Eklund O, Afzal F, Borgström F, Flavin J, Ternouth A, Ojanguren ME, Crespo C, and Baldwin M

Subjects
COPD, Exacerbations, Tiotropium, Glycopyrronium, Cost-effectiveness, Markov cohort model, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Oskar Eklund,1 Faraz Afzal,2 Fredrik Borgström,1 Jason Flavin,3 Andrew Ternouth,4 Maria Eugenia Ojanguren,5 Carlos Crespo,5 Mike Baldwin6 1Quantify Research AB, Stockholm, Sweden; 2Boehringer Ingelheim, Asker, Norway; 3Boehringer Ingelheim, Burlington, ON, Canada; 4Boehringer Ingelheim, Bracknell, Berkshire, UK; 5Boehringer Ingelheim, Sant Cugat del Vallès, Barcelona, Spain; 6Boehringer Ingelheim, Ingelheim, Germany Objectives: Tiotropium (TIO), Spiriva® Handihaler®, is a well-established bronchodilator, LAMA (long acting muscarinic antagonist), for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence from the SPARK trial suggests that TIO is superior to glycopyrronium (GLY), Seebri® Breezhaler®, in terms of severe exacerbations. This modeling study assessed the cost-effectiveness of TIO versus GLY for Canada (CAN), Spain (ESP), Sweden (SWE), and the UK, making use of this new clinical evidence.Methods: A Markov cohort model, with moderate to very severe (Global Initiative for Chronic Obstructive Lung Disease II–IV) COPD patients, was populated with efficacy data from the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) and SPARK trials as well as costs, utilities, and epidemiological data relevant for each country. Treatment efficacy was modeled as improvements in lung function, quality-adjusted life years (QALYs), and as a lowering of the risk of exacerbations (rate of exacerbations). Risks of exacerbations differed between cohorts based on data from SPARK. Health and cost outcomes were simulated over an approximate lifetime horizon, starting from the age of 65 years. Robustness of results was validated in deterministic sensitivity analyses.Results: Over the lifetime horizon, patients treated with TIO accumulated −623 (CAN), 1,066 (ESP), 1,137 (SWE), and −169 (UK), respectively, in incremental costs (€2014). TIO generated better health outcomes compared to GLY in all countries, 0.21 (CAN), 0.25 (ESP), 0.23 (SWE), and 0.23 (UK) in incremental QALYs. The cost per QALY gained was found to be €4,281 and €1,137 for ESP and SWE, respectively, while TIO was found to be cost saving in CAN and the UK. The results were mainly driven by the relative risk of severe exacerbations found in SPARK (GLY/TIO relative risk: 1.43, 95% confidence interval: 1.05–1.97, P=0.025).Conclusion: The results from this study show that TIO is a cost-effective treatment compared to GLY in moderate to very severe COPD. The cost per QALY is well below the existing implicit and explicit willingness-to-pay thresholds. Keywords: COPD, exacerbations, tiotropium, glycopyrronium, cost-effectiveness, Markov cohort model

Published
2016

16. Epidemiology and economic burden of osteoporosis in Greece

Author

Makras, P., Lyritis, G. P., Rizou, S., Drakopoulou, T., Trovas, G., Willers, C., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Borgström, F., and Kanis, J. A.

Subjects
treatment, Greece, fracture, economic burden, epidemiology, European Union, health technology assessment
Abstract

[Extract] The scorecard summarises key indicators of the burden of osteoporosis and its management in the 27 member states of the European Union, as well as the UK and Switzerland (termed EU27+2) [1]. This country-specific report summarises the principal results for Greece.

Published
2022

22. Osteoporosis in Europe: a compendium of country-specific reports

Author

Willers, C., Norton, N., Harvey, N.C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E.V., Borgström, F., and Kanis, J.A.

Subjects
Epidemiology, Incidence, Economic burden, Europe, Treatment, Fracture, Cost of Illness, Humans, Osteoporosis, Orthopedics and Sports Medicine, Female, Original Article, European Union, Health technology assessment, Osteoporotic Fractures
Abstract

Summary This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union plus Switzerland and the UK (EU 27+2). Introduction The aim of this report was to characterize the burden of osteoporosis in each of the countries of the European Union plus Switzerland and the UK in 2019 and beyond. Methods The data on fracture incidence and costs of fractures in the EU27+2 was taken from a concurrent publication in this journal (SCOPE 2021: a new scorecard for osteoporosis in Europe) and country-specific information extracted. The information extracted covered four domains: burden of osteoporosis and fractures; policy framework; service provision; and service uptake. Results The clinical and economic burden of osteoporotic fractures in 2019 is given for each of the 27 countries of the EU plus Switzerland and the UK. Each domain was ranked and the country performance set against the scorecard for all nations studied. Data were also compared with the first SCOPE undertaken in 2010. Fifteen of the 16 score card metrics on healthcare provision were used in the two surveys. Scores had improved or markedly improved in 15 countries, remained constant in 8 countries and worsened in 3 countries. The average treatment gap increased from 55% in 2010 to 71% in 2019. Overall, 10.6 million women who were eligible for treatment were untreated in 2010. In 2019, this number had risen to 14.0 million. Conclusions In spite of the high cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by aging populations, the use of pharmacological prevention of osteoporosis has decreased in recent years, suggesting that a change in healthcare policy concerning the disease is warranted.

Published
2021

26. The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture

Author

Borgström, F., Lekander, I., Ivergård, M., Ström, O., Svedbom, A., Alekna, V., Bianchi, M. L., Clark, P., Curiel, M. D., Dimai, H. P., Jürisson, M., Kallikorm, R., Lesnyak, O., McCloskey, E., Nassonov, E., Sanders, K. M., Silverman, S., Tamulaitiene, M., Thomas, T., Tosteson, A. N. A., Jönsson, B., and Kanis, J. A.

Published
2013
Full Text
View/download PDF

28. An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis

Author

Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Perez, A. Diez, Eastell, R., Hofbauer, L. C., Kanis, J. A., Langdahl, B. L., Lesnyak, O., Lorenc, R., McCloskey, E., Messina, O. D., Napoli, N., Obermayer-Pietsch, B., Ralston, S. H., Sambrook, P. N., Silverman, S., Sosa, M., Stepan, J., Suppan, G., Wahl, D. A., Compston, J. E., and for the Joint IOF–ECTS GIO Guidelines Working Group

Published
2012
Full Text
View/download PDF

31. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

Author

Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., Hofbauer, L. C., Kanis, J. A., Langdahl, B. L., Lesnyak, O., Lorenc, R., McCloskey, E., Messina, O. D., Napoli, N., Obermayer-Pietsch, B., Ralston, S. H., Sambrook, P. N., Silverman, S., Sosa, M., Stepan, J., Suppan, G., Wahl, D. A., Compston, J. E., and Joint IOF-ECTS GIO Guidelines Working Group

Published
2012
Full Text
View/download PDF

41. Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS)

Author

Talevski, J., primary, Sanders, K.M., additional, Watts, J.J., additional, Nicholson, G.C., additional, Seeman, E., additional, Iuliano, S., additional, Prince, R., additional, March, L., additional, Winzenberg, T., additional, Duque, G., additional, Ebeling, P.R., additional, Borgström, F., additional, Kanis, J.A., additional, Stuart, A.L., additional, Beauchamp, A., additional, and Brennan-Olsen, S.L., additional

Published
2021
Full Text
View/download PDF

49. Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?

Author

McCloskey, E. V., Chotiyarnwong, P., Harvey, N. C., Lorentzon, M., Kanis, J. A., for the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group, Prieto-Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyere, O., Carey, J. J., Clark, P., Cooper, C., Curtis, E. M., Dennison, E., Diaz-Curiel, M., Dimai, H. P., Grigorie, D., and Hiligsmann, M.

Subjects
BONE fracture prevention, OSTEOPOROSIS prevention, MEDICAL screening, RISK assessment, POSTMENOPAUSE
Abstract

An editorial is presented on the approaches to improving the management and treatment of patients with osteoporotic fractures are increasingly advocated in many countries. It outlines the management of those presenting with nonhip fractures is also addressed through the establishment of Fracture Liaison Services. An overview of the systematic approaches for the identification of high fracture risk is presented.

Published
2022
Full Text
View/download PDF

50. P054 Clinical outcomes in people with cystic fibrosis treated with lumacaftor/ivacaftor in routine clinical practice in Sweden

Author

Lindblad, A., primary, de Monestrol, I., additional, Gilljam, M., additional, Lindberg, U., additional, Krantz, C., additional, Klackenberg, A., additional, McGarry, L.J., additional, Bhaiwala, Z., additional, Borgström, F., additional, Banefelt, J., additional, Danielsson, L., additional, and Aldvén, M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results